FGF23 and chronic kidney disease: In 2018, Milovanova et al. conducted a prospective, randomized, controlled trial in 79 CKD 3b-4 patients to compare the possibilities of LPD + KA and isolated LPD on their impact on FGF-23, whose plasma changes in patients with advanced CKD are associated with bone mineral disorders, metabolic acidosis, oxidative stress, chronic inflammation, and protein-energy wasting.